According to @DowdEdward, PFE’s revenue decline stems from a one-time COVID mRNA windfall tied to mandates, collapsing booster uptake, and negative word-of-mouth about side effects, creating sustained demand headwinds for the company’s vaccine franchise. Source: @DowdEdward on X (Dec 17, 2025). He adds that continued COVID infections despite vaccination undermined a booster-for-life model, which he argues pressures PFE’s top line and trader sentiment, framing a bearish near-term narrative for the stock. Source: @DowdEdward on X (Dec 17, 2025). The source does not cite any direct cryptocurrency market impact related to this view. Source: @DowdEdward on X (Dec 17, 2025).